Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

April 7, 2024

https://www.globenewswire.com/news-release/2024/04/07/2858854/0/en/Black-Diamond-Therapeutics-Presents-Novel-Real-World-Evidence-of-the-Evolving-EGFR-Mutation-Landscape-in-NSCLC-and-the-Opportunity-for-BDTX-1535-in-an-Oral-Presentation-at-the-2024.html

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC

Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.